PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-272.88%
Both yoy net incomes decline, with TRVN at -35.14%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
77.92%
D&A growth well above TRVN's 17.79%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Deferred tax of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
49.65%
SBC growth well above TRVN's 3.91%. Michael Burry would flag major dilution risk vs. competitor’s approach.
56.13%
Less working capital growth vs. TRVN's 230.12%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.43%
AP growth of 59.43% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-0.47%
Negative yoy usage while TRVN is 230.12%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
85.22%
Some yoy increase while TRVN is negative at -2024.44%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-64.88%
Both yoy CFO lines are negative, with TRVN at -13.82%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
82.30%
Some CapEx rise while TRVN is negative at -34.87%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.30%
We have mild expansions while TRVN is negative at -34.87%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-39.13%
We cut debt repayment yoy while TRVN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-90.34%
Negative yoy issuance while TRVN is 100.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.